Search results
Results From The WOW.Com Content Network
[52] [53] [54] As of July 2021, a large number of drugs had been considered for treating COVID-19 patients. [55] As of November 2022, there was moderate-certainty evidence suggesting that dexamethasone, and systemic corticosteroids in general, probably cause a slight reduction in all-cause mortality (up to 30 days) in hospitalized patients with ...
Although not statistically significant, among these vaccinated participants, there was a reduction in the risk of COVID‑19 related hospitalization or death from any cause. [14] In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID ...
“A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of ...
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
Marik is promoting a treatment of his own devising, a combination of corticosteroids and high-dose ascorbic acid, or vitamin C, as a first-line therapy for patients hospitalized with COVID-19 ...
According to the Centers for Disease Control, COVID-19 hospitalizations rose by 10% in the week of July 15, as compared to the previous week, from 6,444 hospitalizations to 7,109. “Risk of ...
[9] [10] These drugs had been further developed prior to the COVID-19 pandemic for other diseases including SARS. [11] The utility of targeting the 3CL protease in a real world setting was first demonstrated in 2018 when GC376 (a prodrug of GC373) was used to treat the previously 100% lethal cat coronavirus disease, feline infectious ...
At that time, the editors of the journal PLoS Medicine wrote: "Schwitzer's alarming report card of the trouble with medical news stories is thus a wake-up call for all of us involved in disseminating health research-researchers, academic institutions, journal editors, reporters, and media organizations-to work collaboratively to improve the ...